Lead Product(s) : YS2302018,AZD0780
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
AstraZeneca Puts $2B on The Line for Preclinical Heart Disease Drug
Details : AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Brand Name : YS2302018
Molecule Type : Small molecule
Upfront Cash : $100.0 million
October 07, 2024
Lead Product(s) : YS2302018,AZD0780
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
